A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503467-41-00

Acronym

64407564MMY3002

Enrollment

310

Registered

2024-06-28

Start date

2022-10-12

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

Brief summary

Progression-Free Survival

Interventions

DRUGFortecortin® 2 mg Tabletten

DRUGPrivigen 100 mg/ml solution for infusion

DRUGKIOVIG 100 mg/ml solution for infusion

DRUGImnovid 4 mg hard capsules

DRUGPomalidomide

DRUGImnovid 1 mg hard capsules

DRUGDexamethasone Tablets BP 2.0mg

DRUGJNJ-64407564

DRUGDARZALEX 1800 mg solution for injection

DRUGImnovid 3 mg hard capsules

DRUGDexamethason 4 mg JENAPHARM®

DRUGImnovid 2 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival	—

Countries

Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026